Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Eskouhie Tchaparian"'
Autor:
Kathryn Bauerly, Calliandra Harris, Winyoo Chowanadisai, James Graham, Peter J Havel, Eskouhie Tchaparian, Mike Satre, Joel S Karliner, Robert B Rucker
Publikováno v:
PLoS ONE, Vol 6, Iss 7, p e21779 (2011)
We have reported that pyrroloquinoline quinone (PQQ) improves reproduction, neonatal development, and mitochondrial function in animals by mechanisms that involve mitochondrial related cell signaling pathways. To extend these observations, the influe
Externí odkaz:
https://doaj.org/article/3a08a21fed74408484e1a9dfaf2536d5
Autor:
Shubham Pant, Tomislav Dragovich, Christopher Lieu, Antonio Jimeno, Madappa Kundranda, David Menter, Eskouhie Tchaparian, Yuchih C. Chen, Scott Kopetz
Publikováno v:
Investigational new drugs.
CA102N is a covalently bound conjugate of modified nimesulide (Nim) and NaHA, the sodium salt of hyaluronic acid (HA). HA is a natural ligand of cluster of differentiation 44 (CD44), which is over-expressed in colorectal cancer (CRC). CA102N is desig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31eedc82ce4d4dbbcb9e6eece81db263
https://pubmed.ncbi.nlm.nih.gov/36331676
https://pubmed.ncbi.nlm.nih.gov/36331676
Autor:
Eskouhie Tchaparian, Star Lin
Publikováno v:
Cancer Research. 83:2007-2007
Multiple Myeloma (MM) is a rare and incurable hematological malignancy. Despite emerging treatments, there is still an unmet medical need for novel therapeutics to target the inherent and acquired drug resistance associated with MM. CA102L is a conju
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b1f7e85a1de764a6dff37eec1c40c39
https://doi.org/10.1158/1538-7445.am2023-2007
https://doi.org/10.1158/1538-7445.am2023-2007
Publikováno v:
Cancer Research. 81:1312-1312
CA102N is a novel anticancer product designed to deliver its payload (Nim) to cells via the CD44 receptor. CA102N is currently in Phase 1 clinical trial for the treatment of metastatic colorectal cancer (mCRC). The major target of CA102N is the PI3K/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ccb7339acc6317cae31fd012029c7dee
https://doi.org/10.1158/1538-7445.am2021-1312
https://doi.org/10.1158/1538-7445.am2021-1312
Publikováno v:
Cancer Research. 80:5335-5335
It is well documented that COX-2 inhibitors have the potential in preventing or treating colorectal cancer. However, the cardiovascular toxicity of COX-2 inhibitors hampered further development of these inhibitors in cancer management. CA102N is a co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbb06fdcd583042a52098369268bc8b2
https://doi.org/10.1158/1538-7445.am2020-5335
https://doi.org/10.1158/1538-7445.am2020-5335
Publikováno v:
Cancer Research. 79:3901-3901
CA102N is a conjugate of the biological polymer hyaluronic acid (HA) and Nimesulide (Nim), a cyclooxygenase-2 (COX-2) inhibitor that represents a promising new approach to addressing cancer treatment. Similar to an antibody-drug conjugate or a pro-dr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2801aad080eb58168eb44670abd1a700
https://doi.org/10.1158/1538-7445.am2019-3901
https://doi.org/10.1158/1538-7445.am2019-3901
Autor:
Nancy C. Sambol, Francesca T. Aweeka, Jordan W. Tappero, Yngve Bergqvist, Nitin Sukumar, Darren J. Creek, Daniel Blessborn, Shelley A. McCormack, Emmanuel Arinaitwe, Eskouhie Tchaparian, Mary K. Muhindo, Humphrey Wanzira, Abel Kakuru, Victor Bigira, Sunil Parikh
Publikováno v:
The Journal of Infectious Diseases
Background. The pharmacokinetics and pharmacodynamics of lumefantrine, a component of the most widely used treatment for malaria, artemether-lumefantrine, has not been adequately characterized in young children. Methods. Capillary whole-blood lumefan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3ac15ff0847a3294365254769b9533d
http://urn.kb.se/resolve?urn=urn:nbn:se:du-23296
http://urn.kb.se/resolve?urn=urn:nbn:se:du-23296
Autor:
Bradley K. Wong, Yun Ling, Adria E. Colletti, Liyue Huang, Jonathan Roberts, Eskouhie Tchaparian, Xuhai Be, Meghan Langley, Lixia Jin
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 343:316-324
This study was designed to characterize breast cancer resistance protein (Bcrp) knockout Abcg2(-/-) rats and assess the effect of ATP-binding cassette subfamily G member 2 (Abcg2) deletion on the excretion and pharmacokinetic properties of probe subs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9758c2c4c6aee3a7ab4a692397b061c1
https://doi.org/10.1124/jpet.112.197046
https://doi.org/10.1124/jpet.112.197046
Publikováno v:
Drug Metabolism and Disposition. 39:2387-2394
Sandwich-cultured rat hepatocytes are used in drug discovery for pharmacological and toxicological assessment of drug candidates, yet their utility as a functional model for drug transporters has not been fully characterized. To evaluate the system a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddb10b8849cc9c354476165ec83df0bf
https://doi.org/10.1124/dmd.111.039545
https://doi.org/10.1124/dmd.111.039545
Autor:
Louis Lin, Eskouhie Tchaparian
Publikováno v:
Cancer Research. 78:5811-5811
CA102N is a conjugate of HA and H-Nim (N-(4-Amino-2-phenoxyphenyl, methanesulfonamide), a derivative of cyclooxygenase-2 inhibitor Nimesulide, and a CD44 receptor targeted system currently in preclinical development for metastatic colorectal cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c5249a6692d604e0958c61d9683a5fb
https://doi.org/10.1158/1538-7445.am2018-5811
https://doi.org/10.1158/1538-7445.am2018-5811